Next FDA commissioner will reverse Makary’s regulatory streamlining efforts

Healthcare investors and industry lobbyists criticized Makary’s unpredictable regulatory decisions, particularly around drug approvals. A successor aligned with Trump-aligned critics is likely to scale back or reverse recent efforts to speed up clinical trials and drug approvals.

Implied probability (Yes)

68%